Calidi Biotherapeutics, Inc. · AMEX:CLDI
Calidi Biotherapeutics — Biocom Global Life Science Partnering & Investor Conference 2024
18 slides from Calidi Biotherapeutics's conference presentation, Feb 28, 2024
Slide 1: Systemic and Localized Oncolytic Virotherapies
Systemic and Localized Oncolytic Virotherapies Designed to attack every tumor and arm the immune system : Biocom Global Life Science,Partnering & Investor Conference - February 28, 2024 ‘ ~ CALIDi 'BIOTHERAPEUTICS
Slide 2: Calidi Biotherapeutics company overview
CALIDi é) Calidi Biotherapeutics is a clinical-stage biotechnology company that is transforming cancer treatment, with innovative oncolytic virotherapies. Our cutting-edge cell-based technologies protect and deliver oncolytic virotherapies into tumor sites, effectively overcoming the clinical challe
Slide 3: Rapidly Growing OV Market With High Unmet Needs
Rapidly Growing ov Market With High Ur r 7. Le Lar Rapidly growing OV market with high unmet needs Large total addressable market across current indications of focus: 1 6-8 approved competitor base Melanoma, GBM, TNBC, approved OVs Head & Neck, Lung ov $2.48 in ~56k patients across all Calidi $1som"
Slide 4: Calidi Oncology Pipeline
Calidi. Oncology Pipeline icatie i Non-clinical Pivotal Product Platform ‘Target Indications Discovery rs Phase Phase2_ "0 Partner Novi ingress ich TT — Groce ciome QR mee OC. ae sxe Bk Neck, TNBC (Localized administration) Metastatic Solid Tumors & cLp-400 RTNova Lung cancer {Systemic administratio
Slide 5: Why Oncolytic Virotherapy?
Why Oncolytic Virotherapy? Challenges: Oncolytic Virotherapies: Immunotherapy has shown limited 1- Direct and selective killing of Tumor cells effectiveness in treating solid tumors - S due to the immunosuppressive environment within the tumor. 2- Reduce immunosuppression 3- Induce anti-tumor Immune
Slide 6: Calidi Overcomes the Obstacles to Oncolytic Viral Therapy
Calidi Overcomes the Obstacles to Oncolytic Viral Therapy Unprotected Oncolytic Virus Allogeneic Oncolytic Virus-Loaded Stem Cells ‘Stem cell loaded with active Rapid inactivation Oncolytic byimmune | Oncolytic Viruses Stem cell protects uses system = (ov) and amplifies OV Naked oncolytic viruses ar
Slide 7: Calidi's Three Lead Programs
Calidi’s Three Lead Programs CLD-101 (NeuroNova) Clinical trial Phase 1/1b CLD-201 (SuperNova) Targeting clinic 2H 2024 CLD-400 (RTNova) Pre-clinical Indication: Recurrent and newly diagnosed High Grade Glioma Tumor selective Virotherapy: Adenovirus: CRAD-s-Pk7 Delivery vehicle/potentiator: Indicati
Slide 8: CLD-101 in High grade Glioma (HGG)
CLD-101 in High grade Glioma (HGG) Completed: Phase 1 (NWU) Ongoing: Phase 1 (COH) In preparation: Phase 1b (NWU) Single dose ultiple dose multiple dose in newly diagnosed HGG in recurrent HGG in newly diagnosed HGG * Treatment was safe and * 1°" Objective: analyze safety * 12" Objective: analyze sa
Slide 9: CLD-201 in Advanced Solid Tumors
CLD-201 in Advanced Solid Tumors Completed: Safety Study In Preparation: Phase 1 (Calidi) Autologous settings - Single dose Allogeneic, off-the shelf - multiple dose Treatment was safe a able New allogeneic program developed to reach wider cancer population cGMP Final Drug Product Manufacturing to b
Slide 10: Calidi's Systemic Approach (RTNova program)
Calidi’s Systemic Approach (RTNova program) v New treatment option for advanced metastatic disease, or lung Cancer v Simple, cost-effective IV administration avoiding the need for image-guided delivery. CALIDI © 2024 Calidi Biotherapeutics, Inc. | Company Proprietary; Patents issued and pending Page
Slide 11: Redtail Vaccinia virus comet assay
CALIDi (“Redtail”) Pre Comet assay of two distinct vaccinia viruses. Vaccinia Viruses are genetically engineered to express TurboFP635 (red fluorescence). Vaccinia virus strain CAL2 producing low EEV particle <1% A short and round plaque signifies that the virus mainly spreads from cell to cell. Red
Slide 12: Effective Manufacturing of Stable Enveloped Viruses, Resistant to Humoral Immunity
Effective Manufacturing of Stable Enveloped Viruses, Resistant to Humoral Immunity Potency of EEV after different > Anovel technique for purifying extracellular enveloped viruses manufacturing protocol. (EEVs), was required. 100 EnvelopedRT01 ry 3 804 T > Clinically relevant manufacturing process is
Slide 13: Development of a New Enveloped Vaccinia Backbone Designed for Systemic Delivery
Development of a New Enveloped Vaccinia Backbone Designed for Systemic Delivery 1- New tumor selective Vaccinia virus (RT) 2- High production of enveloped viruses by manufacturing host cell and at tumor site. Genetically encoded. 3- A large insertion capacity (25-45Kb), allowing delivering of any th
Slide 14: Only Enveloped virotherapies can survive inactivation by human serum
Only Enveloped virotherapies can survive inactivation by human serum. Critical step to achieve systemic delivery Standard media = Human Serum 12.4% Survival 79.3% Survival CALIDi 024 Calidi Botherapeutics, Inc, | Company Proprietary; Patents issued and pe Page 14
Slide 15: Systemic Administration of envRT01 Can Target and Eliminate Multiple Tumors
Systemic Administration of envRTO1 Can Target‘and Eliminate: Multiple Tumors After systemic administration, envRT-01 Mouse model bearing 3 different human solid tumor types (enveloped RT-01) can target and express Untreated envRT-01 % Tumor Growth inhibition selected payload (such as TurboFP635) in
Slide 16: envRT-01 Induces Major Modulation of Tumor Microenvironment
envRT-01 Induces INV lajor Modulation of Tum Immunohistochemistry data indicates envRT-01 treatment induces major infiltration of CD8 and CD4 T cells and reduction of myeloid population (Breast cancer tumors). Untreated tumor envRT-01 Color legend CD11b (Myeloid) Vaccinia AP | (tumor) CD87, C4 | Mye
Slide 17: Bringing a Clinical Revolution by Using Cells to Deliver Oncolytic Virotherapies
Clinical Revolution es By Using Cells, or Ce! Oncolytic Virotherapies to a New Therapeutic Aiming to provide a safe and tolerable therapeutic approach Systemic and localized oncolytic immunotherapies y P Off-the-shelf platforms. Using proprietary, scalable, commercial viable state-of-the-art approac
Slide 18: Contact: Allan J. Camaisa and management
Allan J. Camaisa CEO/Chair of the Board Cell: +1 858 444 7059 email: acamaisa@calidibio.com Stephen Thesing Chief Business Officer Cell: +1 858.386.3776 email: sthesing@calidibio.com = Antonio F. Santidrian, PharmD, PhD Chief Scientific Officer BIOTHERAPEUTECS Cell: +1 858 405 5829 magi Ealidi Bioth
Calidi Biotherapeutics — Biocom Global Life Science Partnering & Investor Conference 2024 on 6ix